Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of celiac disease for each…

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the total and diagnosed prevalence of…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key celiac disease patient populations, covering 171 countries and more…

Many well-established therapies are available to treat ulcerative colitis (UC) in the EU5. TNF-alpha inhibitors (Janssen’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and…

Multiple well-established therapies are available to treat Crohn’s disease (CD). The mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen / Merck’s Remicade, AbbVie / Eisai’s…

The Company Franchise Analysis (CFA) provides a comprehensive evaluation of the franchise, including benchmarking, strategic insights, and an overview of marketed products. It highlights key market…

The Company Franchise Analysis (CFA) provides a comprehensive evaluation of the franchise, including benchmarking, strategic insights, and an overview of marketed products. It highlights key market…

2023 marks a pivotal year for the autoimmune space as numerous releases of biosimilar adalimumab challenge the market dominance of AbbVie’s Humira, one of the best-selling brands in the United…

Clarivate Epidemiology’s coverage of celiac disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus, characterized by an accumulation of eosinophils. It can cause difficulty with swallowing food and has…